Identification of prognostic gene signatures of glioblastoma: A study based on TCGA data analysis

Neuro-Oncology

Volumn 15, Issue 7, 2013, Pages 829-839

  Kim, Yong Wan ^a   Koul, Dimpy ^b   Kim, Se Hoon ^b   Lucio Eterovic, Agda Karina ^b   Freire, Pablo R ^b   Yao, Jun ^b   Wang, Jing ^b   Almeida, Jonas S ^b   Aldape, Ken ^b   Yung, W K Alfred ^b  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

comparative genomic hybridization; EMT; gene expression; glioblastoma; prognostic marker; TCGA

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; GELATINASE A; GELATINASE B; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COPY NUMBER VARIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE IDENTIFICATION; GLIOBLASTOMA; HUMAN; LONG TERM SURVIVAL; OVERALL SURVIVAL; PHENOTYPE; SHORT TERM SURVIVAL; SURVIVAL FACTOR; SURVIVAL RATE; SURVIVAL TIME;

COMPARATIVE GENOMIC HYBRIDIZATION; EMT; GENE EXPRESSION; GLIOBLASTOMA; PROGNOSTIC MARKER; TCGA;

BRAIN NEOPLASMS; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DNA COPY NUMBER VARIATIONS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOMICS; GLIOBLASTOMA; HUMANS; MODELS, STATISTICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84879405541     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not024     Document Type: Article

References (53)

1. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3): 157-173. (Pubitemid 43357943)
2. Fukuda ME, Iwadate Y, Machida T, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 2005; 65(12): 5190-5194. (Pubitemid 40827328)
3. Yamanaka R. Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med. 2008; 14(5): 228-235.
4. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216): 1061-1068.
5. Freire P, Vilela M, Deus H, et al. Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One. 2008; 3(12): e4076.
6. Hodgson JG, Yeh RF, Ray A, et al. Comparative analyses of gene copy number and mRNA expression in GBM tumors and GBM xenografts. Neuro Oncol. 2009; 11(5): 477-487.
7. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1): 98-110.
8. National Cancer Institute. REMBRANDT home page 2005; http://rembrandt. nci.nih.gov.
9. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005; 11(18): 6422-6430. (Pubitemid 41338978)
10. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics. 2003; 19(18): 2448-2455. (Pubitemid 38016644)
11. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer informatics. 2007; 3: 11-17. (Pubitemid 47075796)
12. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004; 5(4): 557-572. (Pubitemid 41180205)
13. Alonso MM, Fueyo J, Shay JW, et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst. 2005; 97(21): 1589-1600. (Pubitemid 41662713)
14. Kim SH, Kim H, Kim TS. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors. Acta Neuropathol. 2005; 110(1): 27-38. (Pubitemid 41131194)
15. Li A, Walling J, Ahn S, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 2009; 69(5): 2091-2099.
16. Kehlen A, Thiele K, Riemann D, Rainov N, Langner J. Interleukin-17 stimulates the expression of IkappaB alpha mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines. J Neuroimmunol. 1999; 101(1): 1-6. (Pubitemid 29505167)
17. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol. 2002; 9(3): 505-511. (Pubitemid 34920572)
18. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006; 66(23): 11502-11513. (Pubitemid 46009984)
19. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009; 41(8): 905-908.
20. Takahashi E, Nagano O, Ishimoto T, et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelialmesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem. 2010; 285(6): 4060-4073.
21. Moody SE, Perez D, Pan TC, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005; 8(3): 197-209. (Pubitemid 41317591)
22. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996; 271(5248): 509-512. (Pubitemid 26044470)
23. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004; 6(3): 227-235. (Pubitemid 39136506)
24. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5): 510-522.
25. Loeper S, Romeike BF, Heckmann N, et al. Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenetics and Cell Genetics. 2001; 94(1-2): 1-8. (Pubitemid 33036034)
26. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005; 353(8): 811-822.
27. Riddick G, Fine HA. Integration and analysis of genome-scale data from gliomas. Nature reviews. Neurology. 2011; 7(8): 439-450.
28. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010; 12(1): 49-57.
29. Yan X, Ma L, Yi D, et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci USA. 2011; 108(4): 1591-1596.
30. Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nature Reviews. Neuroscience. 2011; 12(9): 495-508.
31. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol. 2002; 20(10): 2495-2499. (Pubitemid 34525735)
32. Jones TS, Holland EC. Molecular pathogenesis of malignant glial tumors. Toxicologic pathology. 2011; 39(1): 158-166.
33. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4): 265-273.
34. Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010; 463(7279): 318-325.
35. Tso CL, Shintaku P, Chen J, et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006; 4(9): 607-619. (Pubitemid 44497214)
36. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009; 27(10): 2383-2392.
37. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain: A Journal of Neurology. 2007; 130(Pt 10): 2596-2606. (Pubitemid 47511715)
38. Kong D, Li Y, Wang Z, Sarkar FH. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?. Cancers (Basel). 2011; 3(1): 716-729.
39. Kashyap V, Rezende NC, Scotland KB, et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells and Development. 2009; 18(7): 1093-1108.
40. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Current Cancer Drug Targets. 2010; 10(3): 268-278.
41. Gallo D, Ferlini C, Scambia G. The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer. Current Drug Targets. 2010; 11(4): 474-481.
42. Arslantas A, Artan S, Oner U, et al. The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurgical Review. 2004; 27(1): 58-64. (Pubitemid 38146175)
43. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004; 22(10): 1926-1933. (Pubitemid 41095185)
44. Misra A, Pellarin M, Hu L, et al. Chromosome transfer experiments link regions on chromosome 7 to radiation resistance in human glioblastoma multiforme. Genes, Chromosomes and Cancer. 2006; 45(1): 20-30. (Pubitemid 46930858)
45. Bowen KA, Doan HQ, Zhou BP, et al. PTEN loss induces epithelial- mesenchymal transition in human colon cancer cells. Anticancer Research. 2009; 29(11): 4439-4449.
46. Langlois MJ, Bergeron S, Bernatchez G, et al. The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS One. 2010; 5(12): e15742.
47. Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H, Yuan J. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res. 2006; 66(4): 1929-1939.
48. Shorning BY, Griffiths D, Clarke AR. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One. 2011; 6(1): 0-e16209.
49. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet. 2001; 27(2): 222-224. (Pubitemid 32157454)
50. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes and Development. 2009; 23(6): 675-680.
51. Martin P, Liu YN, Pierce R, et al. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. The American Journal of Pathology. 2011; 179(1): 422-435.
52. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009; 41(8): 899-904.
53. Debies MT, Gestl SA, Mathers JL, et al. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/ p53 pathway lesions but not p16 Ink4a loss. J Clin Invest. 2008; 118(1): 51-63.